Modality
Nanobody
MOA
PI3Ki
Target
KRASG12C
Pathway
Angiogenesis
Celiac
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Jul 2030
Phase 1Current
NCT07747230
1,058 pts·Celiac
2021-02→TBD·Terminated
NCT07637763
2,094 pts·Celiac
2018-03→2030-07·Terminated
3,152 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-064.3y awayPh2 Data· Celiac
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2030-07-06 · 4.3y away
Celiac
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07747230 | Phase 1/2 | Celiac | Terminated | 1058 | EDSS |
| NCT07637763 | Phase 1/2 | Celiac | Terminated | 2094 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |